Nutra Pharma is providing updates on their work in improving capabilities and certifications in their laboratory for drug production and validation. February 23, 2021 -- Plantation, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, is

February 12, 2021 -- Plantation, Florida -- Nutra Pharma Corporation (OTC: NPHC), a biotechnology company marketing Nyloxin®, Pet Pain-Away and Equine Pain-Away in the over-the-counter (OTC) pain management market and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV) and Pain, announced today that they are focusing on their intellectual property portfolio and have engaged their IP attorneys at Christopher & Weisberg P.A. “Inte